about
Cardiomyopathy classification: ongoing debate in the genomics eraEctopic expression of KCNE3 accelerates cardiac repolarization and abbreviates the QT intervalDown-regulation of the M6P/IGF-II receptor increases cell proliferation and reduces apoptosis in neonatal rat cardiac myocytesModel-specific selection of molecular targets for heart failure gene therapyGene delivery technologies for cardiac applicationsTargeting S100A1 in heart failureImprovement in survival and cardiac metabolism after gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase in a rat model of heart failureCytoprotection by the modulation of mitochondrial electron transport chain: the emerging role of mitochondrial STAT3Transfer of the full-length dystrophin-coding sequence into muscle cells by a dual high-capacity hybrid viral vector with site-specific integration abilityPositron emission tomography imaging of cardiac reporter gene expression in living ratsCatheter-based antegrade intracoronary viral gene delivery with coronary venous blockade.Comparative analysis of parvalbumin and SERCA2a cardiac myocyte gene transfer in a large animal model of diastolic dysfunction.Gene therapy for cardiovascular disorders: is there a future?Mixed signals in heart failure: cancer rules.New molecular insights into heart failure and cardiomyopathy: potential strategies and therapies.Targeting calcium cycling proteins in heart failure through gene transfer.Targeting signaling pathways in heart failure by gene transfer.Gene therapy for cardiovascular angiogenesis.Gene therapy progress and prospects: noninvasive imaging of gene therapy in living subjects.Myocardial regeneration: present and future trends.Restoration of mechanical and energetic function in failing aortic-banded rat hearts by gene transfer of calcium cycling proteins.Transcriptomic biomarkers for individual risk assessment in new-onset heart failure.Stem cells as biological heart pacemakers.From gene therapy and stem cells to clinical electrophysiology.Gene therapy in the treatment of heart failure.Radionuclide reporter gene imaging for cardiac gene therapy.Current strategies for myocardial gene delivery.Molecular basis of diastolic dysfunction.Experimental molecular and stem cell therapies in cardiac electrophysiology.Antiplatelet therapy attenuates subcellular remodelling in congestive heart failure.Abrogation of ventricular arrhythmias in a model of ischemia and reperfusion by targeting myocardial calcium cycling.Advances in gene-based therapy for heart failure.Refilling Intracellular Calcium Stores.Stem cell therapy for electrophysiological disorders.Dual gene therapy with SERCA1 and Kir2.1 abbreviates excitation without suppressing contractility.Hope for heart failure.Lipidoid mRNA Nanoparticles for Myocardial Delivery in Rodents.'Advanced' generation lentiviruses as efficient vectors for cardiomyocyte gene transduction in vitro and in vivo.Left ventricular targeting of reporter gene expression in vivo by human BNP promoter in an adenoviral vector.CRNK gene transfer improves function and reverses the myosin heavy chain isoenzyme switch during post-myocardial infarction left ventricular remodeling.
P2860
Q21284968-0670D0C7-D1AE-4467-AB4B-6D48A3CE9F58Q24551736-6C455FF0-A453-4855-96A6-0DFFAAEF39C8Q24798846-8F354943-AFD0-407C-9E2E-1FB22447FB3CQ26823061-08893A9F-534B-4ED2-A1A4-23FFDEB1DFFDQ26863362-1916918D-A816-4D51-BB57-82F57284B52BQ28259868-0DCC611D-0322-480A-931C-3C7865B224FEQ28354203-9266F02E-4301-4DC2-BC67-A6EF7E7F604DQ28396645-019537DD-3FC4-4B38-B646-48B24FAA9B99Q33834104-36EA6513-A957-49E7-9F7B-06DE7E5098B5Q34134407-564853C0-CA10-4C07-B18F-581B5A5235F8Q34191737-5A83EA47-40CC-4D77-A854-50251C865430Q34321370-CA953DDD-FFEE-456D-91D0-CBC02154FC1AQ34497315-66A414B4-B5BC-4397-96D3-3D0A55452B22Q34584027-B9469BEA-21AB-4E92-B2D9-4D95FE06EA2BQ34782396-27872B66-3508-4E88-A978-94578A198CF7Q35037546-7E600A7F-B390-4E4C-957D-EB449E6299FDQ35095401-DB3CFBFC-0A64-4045-8DEA-8A278EB64137Q35164797-BF50AA7C-F644-49FC-B860-68C023959DC9Q35623922-758887A3-650A-4C8C-9B42-CDE47BD3F141Q35631316-AD91739E-4293-4A4B-B156-A3C3499D10AAQ35933316-A57A22B3-F3EB-4AEF-A5B8-DBD4C4CE0A4FQ36126734-7BD9741B-9A15-46F8-B2FE-EA8BFDA77954Q36327036-E5E4D25F-0219-41BB-BC8F-3E4C4C4933C3Q36596746-0578F385-9AFF-4634-9FBE-CCA087B1D006Q36786243-9CFF76D7-C97B-4092-9FFF-E3EB81B9F620Q36803909-E482353D-336F-49CC-B861-3AE41744438EQ36931967-0454F7D1-DF08-4FF6-B1D0-B485DB9D4F6BQ37099714-5540F013-A97D-4474-A264-8D95FB15A70DQ37122811-EAAC4707-BCAB-42D7-B85B-C31961996867Q37568760-D14006DA-4E37-4D93-8DC1-84CB9AF240DBQ37682472-C5FD59EF-B95A-4737-B590-F835038D1549Q37766138-932DCD6C-FBD6-4758-BFDF-57A37AB5B4D5Q37822275-38889459-6479-40B7-94D2-04EDF956C75DQ38129803-0829CA41-169F-473E-B423-D4C3E9482DF9Q39737461-636ECDFD-99C2-4DD2-B0FD-2EF19EAD68CFQ40231910-9C418332-3D66-41BF-9581-FD4A0F6F010EQ40445304-400EF97F-77E9-4D6A-BDBB-5BCFA82AB625Q40655750-0A4CCEA5-D725-4453-95D8-45E95FD4DCEAQ40703867-98809075-4A8D-40C7-BC96-079BFBD87E63Q42198000-D81A9E5F-2A02-4067-9D7C-014C5BF8E906
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մարտին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Prospects for gene therapy for heart failure.
@ast
Prospects for gene therapy for heart failure.
@en
type
label
Prospects for gene therapy for heart failure.
@ast
Prospects for gene therapy for heart failure.
@en
prefLabel
Prospects for gene therapy for heart failure.
@ast
Prospects for gene therapy for heart failure.
@en
P2093
P356
P1433
P1476
Prospects for gene therapy for heart failure.
@en
P2093
Rosenzweig A
del Monte F
P304
P356
10.1161/01.RES.86.6.616
P577
2000-03-01T00:00:00Z